Anticalins are recombinantly engineered lipocalins, endogenous low-molecular weight human proteins that naturally bind, store and transport a wide spectrum of molecules.
The tie up includes an option of expansion following the delivery of a successful candidate to Takeda.
Further deal terms and financial details were not disclosed.
TSF president and CSO Mary Haak-Frendsch said that Pieris’ Anticalin technology complements their existing capabilities by enabling a novel approach to targets where differentiation from traditional antibodies is required.